Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications-Reference-Cited by-同舟云学术

Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications

Published:2019-11-13 Issue:3 Volume:20 Page:223-228
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Helfer Hélène,Siguret Virginie,Mahé Isabelle

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40256-019-00382-0.pdf

Reference31 articles.

1. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

2. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, ACC/AHA Task Force Members, Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–94.

3. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452–66.

4. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39(2):107–12.

5. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26(Suppl 2):24–38.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study;Journal of Thrombosis and Haemostasis;2024-07

2. Traduction et republication de : « Prise en charge de la maladie thromboembolique veineuse associée au cancer chez les populations vulnérables »;La Revue de Médecine Interne;2024-06

3. Thromboembolic phenomena in patients with nephrotic syndrome: pathophysiology, risk factors, prophylaxis and treatment;British Journal of Hospital Medicine;2024-01-02

4. Management of cancer-associated thromboembolism in vulnerable population;Archives of Cardiovascular Diseases;2024-01

5. Sulfated modification, basic characterization, antioxidant and anticoagulant potentials of polysaccharide from Sagittaria trifolia;Arabian Journal of Chemistry;2023-07